Capricor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.

About CAPR

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. 

CEO
Linda Marbán
CEOLinda Marbán
Employees
102
Employees102
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1996
Founded1996
Employees
102
Employees102

CAPR Key Statistics

Market cap
584.29M
Market cap584.29M
Price-Earnings ratio
-10.74
Price-Earnings ratio-10.74
Dividend yield
Dividend yield
Average volume
1.50M
Average volume1.50M
High today
$14.63
High today$14.63
Low today
$12.75
Low today$12.75
Open price
$14.00
Open price$14.00
Volume
2.66M
Volume2.66M
52 Week high
$23.40
52 Week high$23.40
52 Week low
$3.52
52 Week low$3.52

CAPR News

TipRanks 1d
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges

Capricor Therapeutics, Inc. ((CAPR)) has held its Q4 earnings call. Read on for the main highlights of the call. Capricor Therapeutics, Inc. recently held its...

TipRanks 3d
Capricor Therapeutics Stock Surges on Q4 Results and Promising New Therapy

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading. This comes on th...

TipRanks 3d
Capricor Therapeutics Reports 2024 Financial Results

Capricor Therapeutics, Inc. ( (CAPR) ) has released its Q4 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented to its investo...

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

More CAPR News

Simply Wall St 4d
Capricor Therapeutics, Inc. Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely

Capricor Therapeutics, Inc. ( ) shareholders won't be pleased to see that the share price has had a very rough month, dropping 27% and undoing the prior period'...

Capricor Therapeutics, Inc. Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
TipRanks 6d
Promising Long-Term Efficacy of Capricor’s Deramiocel in DMD Spurs Buy Rating

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report) today and set a price target of $77.00. Jose...

TipRanks 6d
Capricor Therapeutics announces long-term data from HOPE-2 OLE study

Capricor Therapeutics (CAPR) announced long-term data from its ongoing HOPE-2 open label extension clinical trial, demonstrating the potential of the Company’s...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.